Cardiac hypertrophy is exacerbated in aged mice lacking the Osteoprotegerin gene

Cardiovascular Research

Volumn 110, Issue 1, 2016, Pages 62-72

  Hao, Yilin ^a   Tsuruda, Toshihiro ^a   Sekita Hatakeyama, Yoko ^a   Kurogi, Syuji ^b   Kubo, Keishi ^a   Sakamoto, Sumiharu ^a   Nakamura, Midori ^c   Udagawa, Nobuyuki ^c   Sekimoto, Tomohisa ^b   Hatakeyama, Kinta ^d   Chosa, Etsuo ^b   Asada, Yujiro ^a   Kitamura, Kazuo ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c MATSUMOTO DENTAL UNIVERSITY   (Japan)

^d NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Age; Heart failure; Hypertrophy; Osteoporosis

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CASPASE 3; COLLAGENASE 3; DEATH RECEPTOR 5; DIPEPTIDYL CARBOXYPEPTIDASE; GELATINASE A; GELATINASE B; OSTEOPROTEGERIN; PROCOLLAGEN; PROCOLLAGEN ALPHA1; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT OSTEOPROTEGERIN; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE EXACERBATION; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; GENE EXPRESSION; GENE FUNCTION; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE WALL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HYPERTENSION; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOLOGY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; TRANSGENIC MOUSE; TRANSTHORACIC ECHOCARDIOGRAPHY; WESTERN BLOTTING; WILD TYPE; AGING; ANIMAL; BLOOD PRESSURE; CARDIOMEGALY; FIBROSIS; GENETICS; HEART VENTRICLE; HEART VENTRICLE REMODELING; METABOLISM; PHYSIOLOGY;

AGING; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; FIBROSIS; HEART VENTRICLES; MICE; MICE, TRANSGENIC; OSTEOPROTEGERIN; VENTRICULAR REMODELING;

EID: 84966289973     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvw025     Document Type: Article

References (49)

1. Lazzarini V, Mentz RJ, Fiuzat M, Metra M, O'Connor CM. Heart failure in elderly patients: distinctive features and unresolved issues. Eur J Heart Fail 2013;15:717-723.
2. Butler J, Kalogeropoulos AP, Georgiopoulou VV, Bibbins-Domingo K, Najjar SS, Sutton-Tyrrell KC, Harris TB, Kritchevsky SB, Lloyd-Jones DM, Newman AB, Psaty BM. Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study. Heart 2011;97:1304-1311.
3. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, Grobbee DE. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J 1999;20:447-455.
4. Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 2006;113:799-805.
5. Cicoira M, Davos CH, Florea V, Shamim W, Doehner W, Coats AJ, Anker SD. Chronic heart failure in the very elderly: clinical status, survival, and prognostic factors in 188 patients more than 70 years old. Am Heart J 2001;142:174-180.
6. Komajda M, Hanon O, Hochadel M, Lopez-Sendon JL, Follath F, Ponikowski P, Harjola VP, Drexler H, Dickstein K, Tavazzi L, Nieminen M. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J 2009;30:478-486.
7. Mentz RJ, Greene SJ, Ambrosy AP, Vaduganathan M, Subacius HP, Swedberg K, Maggioni AP, Nodari S, Ponikowski P, Anker SD, Butler J, Gheorghiade M. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circ Heart Fail 2014;7:401-408.
8. Güder G, Rutten FH. Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence. Curr Heart Fail Rep 2014;11:337-346.
9. Nerpin E, Ingelsson E, Risérus U, Sundström J, Andren B, Jobs E, Larsson A, Lars L, Arnlöv J. The association between glomerular filtration rate and left ventricular function in two independent community-based cohorts of elderly. Nephrol Dial Transplant 2014;29:2069-2074.
10. Sennerby U, Melhus H, Gedeborg R, Byberg L, Garmo H, Ahlbom A, Pedersen NL, Michaëlsson K. Cardiovascular diseases and risk of hip fracture. JAMA 2009;302:1666-1673.
11. Carbone L, Buzková P, Fink HA, Lee JS, Chen Z, Ahmed A, Parashar S, Robbins JR. Hip fractures and heart failure: findings from the Cardiovascular Health Study. Eur Heart J 2010;31:77-84.
12. Lyons KJ, Majumdar SR, Ezekowitz JA. The unrecognized burden of osteoporosisrelated vertebral fractures in patients with heart failure. Circ Heart Fail 2011;4:419-424.
13. van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16, 294 patients. Circulation 2008;118:1946-1952.
14. Ueland T, Yndestad A, Dahl CP, Gullestad L, Aukrust P. TNF revisited: osteoprotegerin and TNF-related molecules in heart failure. Curr Heart Fail Rep 2012;9:92-100.
15. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
16. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137-142.
17. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597-3602.
18. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268.
19. Nakamichi Y, Udagawa N, Kobayashi Y, Nakamura M, Yamamoto Y, Yamashita T, Mizoguchi T, Sato M, Mogi M, Penninger JM, Takahashi N. Osteoprotegerin reduces the serum level of receptor activator of NF-kB ligand derived from osteoblasts. J Immunol 2007;178:192-200.
20. Yasuda H, Shima N, Nakagawa N, Mochizuki S, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-1337.
21. Schoppet M, Ruppert V, Hofbauer LC, Henser S, Al-Fakhri N, Christ M, Pankuweit S, Maisch B. TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. Biochem Biophys Res Commun 2005;338:1745-1750.
22. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R, Austrian Study Group on Normative Values of Bone Metabolism. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003;32:681-686.
23. Omland T, Drazner MH, Ueland T, AbedinM, Murphy SA, AukrustP, deLemos JA. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007;49:1392-1399.
24. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005;111:2461-2468.
25. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, Squire IB, Gullestad L, Bollerslev J, Dickstein K, Aukrust P. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004;44:1970-1976.
26. Koyama S, Tsuruda T, Ideguchi T, Kawagoe J, Onitsuka H, Ishikawa T, Date H, Hatakeyama K, Asada Y, Kato J, Kitamura K. Osteoprotegerin is secreted into the coronary circulation: a possible association with the renin-Angiotensin system and cardiac hypertrophy. Horm Metab Res 2014;46:581-586.
27. Rottman JN, Ni G, Khoo M, Wang Z, Zhang W, Anderson ME, Madu EC. Temporal changes in ventricular function assessed echocardiographically in conscious and anesthetized mice. J Am Soc Echocardiogr 2003;16:1150-1157.
28. Tsuruda T, Kato J, Kitamura K, Kuwasako K, Imamura T, Koiwaya Y, Tsuji T, Kangawa K, Eto T. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension 1998;31:505-510.
29. Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res 2011;108:1392-1412.
30. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006;154:75-81.
31. Noheria A, Mosley TH, Kullo IJ. Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension. Am J Hypertens 2010;23:767-774.
32. Røysland R, Masson S, Omland T, Milani V, Bjerre M, Flyvbjerg A, Di Tano G, Misuraca G, Maggioni AP, Tognoni G, Tavazzi L, Latini R, Investigators G-H. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial. Am Heart J 2010;160:286-293.
33. Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney JF, Rong J, Corey D, Hoffmann U, Fox CS, Vasan RS, Benjamin EJ, O'Donnell CJ, Kathiresan S. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010;30:1849-1854.
34. Mosheimer BA, Kaneider NC, Feistritzer C, Djanani AM, Sturn DH, Patsch JR, Wiedermann CJ. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab 2005;90:2964-2971.
35. Tousoulis D, Siasos G, Maniatis K, Oikonomou E, Kioufis S, Zaromitidou M, Paraskevopoulos T, Michalea S, Kollia C, Miliou A, Kokkou E, Papavassiliou AG, Stefanadis C. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol 2013;167:1924-1928.
36. Xiang GD, Xu L, Zhao LS, Yue L, Hou J. The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes 2006;55:2126-2131.
37. Takeda N, Manabe I, Uchino Y, Eguchi K, Matsumoto S, Nishimura S, Shindo T, Sano M, Otsu K, Snider P, Conway SJ, Nagai R. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 2010;120:254-265.
38. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002;90:520-530.
39. López B, González A, Querejeta R, Larman M, Díez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006;48:89-96.
40. González A, Ravassa S, Beaumont J, López B, Díez J. New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol 2011;58:1833-1843.
41. van Empel VP, Bertrand AT, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. Cardiovasc Res 2005;67:21-29.
42. Drazner MH. The progression of hypertensive heart disease. Circulation 2011;123:327-334.
43. Bharti AC, Takada Y, Shishodia S, Aggarwal BB. Evidence that receptor activator of nuclear factor (NF)-kB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kB-independent and TRAF6-dependent mechanism. J Biol Chem 2004;279:6065-6076.
44. Ock S, Ahn J, Lee SH, Park H, Son JW, Oh JG, YangDK, Lee WS, Kim HS, Rho J, Oh GT, Abel ED, Park WJ, Min JK, Kim J. Receptor activator of nuclear factor-kB ligand is a novel inducer of myocardial inflammation. Cardiovasc Res 2012;94:105-114.
45. Helske S, Kovanen PT, Lindstedt KA, Salmela K, Lommi J, Turto H, Werkkala K, Kupari M. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail 2007;9:357-363.
46. Leistner DM, Seeger FH, Fischer A, Röxe T, Klotsche J, Iekushi K, Seeger T, Assmus B, Honold J, Karakas M, Badenhoop K, Frantz S, Dimmeler S, Zeiher AM. Elevated levels of the mediator of catabolic bone remodeling RANKL in the bone marrow environment link chronic heart failure with osteoporosis. Circ Heart Fail 2012;5:769-777.
47. Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 1999;59:2770-2775.
48. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002;347:175-184.
49. Kerr NM, Cassinelli HR, DiMeglio LA, Tau C, Tüysüz B, Cundy T, Vincent AL. Ocular manifestations of juvenile Paget disease. Arch Ophthalmol 2010;128:698-703.